Search results for "COMORBIDITY"

showing 10 items of 799 documents

Consequences and comorbidities associated with obesity

2017

This chapter reviews the importance of diabetes as a major complication of obesity, starting with examining the epidemiological relationship between diabetes and obesity. It is clear from the epidemiological data reported that obesity is strongly associated with onset and, in particular, the premature onset, of type 2 diabetes. However, in established heart disease and heart failure, obesity is associated with lower mortality. The chapter considers the epidemiological evidence linking adiposity with the development of cancer, and describes the proposed mechanisms by which excess body fat may impact on cancer risk. The global prevalence of osteoarthritis continues to rise, both because of an…

Gerontologymedicine.medical_specialtyBinge eatingHeart diseasebusiness.industry030209 endocrinology & metabolismType 2 diabetesmedicine.diseaseObesityComorbidity03 medical and health sciences0302 clinical medicineDiabetes mellitusEpidemiologymedicine030212 general & internal medicinemedicine.symptombusinessPsychosocial
researchProduct

The relationship between depression and frailty syndrome: a systematic review

2014

Frailty is a geriatric syndrome characterised by the clinical presentation of identifiable physical alterations such as loss of muscle mass and strength, energy and exercise tolerance, and decreased physiological reserve. Frailty and depressive symptoms are common issues facing older adults and may be associated. It is not clear if the depression facilitates the appearance of frailty syndrome or vice versa or these two coexist independently in the same individuals.We performed searches in several databases (Embase, PubMed, CINAHL, Scopus, and PsycINFO) papers published between November 2003 to February 2014 about frailty syndrome and depression in people aged 65 and older published and the …

Gerontologymedicine.medical_specialtyDepressionbusiness.industryFrail ElderlyFrailty syndromeScopusComorbidityCINAHLPsycINFOmedicine.diseaseMuscle massMental healthPsychiatry and Mental healthmedicineHumansGeriatrics and GerontologyPshychiatric Mental HealthPsychiatrybusinessGerontologyDepressive symptomsDepression (differential diagnoses)AgedAging & Mental Health
researchProduct

Preventing and managing herpes zoster: key actions to foster healthy aging

2015

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can prot…

Gerontologymedicine.medical_specialtyPopulation ageingAgingSettore MED/17 - Malattie InfettiveImmunosenescenceCost-Benefit AnalysisHerpes zosterAlternative medicinePsychological interventionSocio-culturaleDiseaseSettore MED/42 - Igiene Generale E ApplicataQuality of life (healthcare)medicineHerpes Zoster VaccineHumansHerpes zoster; Immunosenescence; Vaccine; Aged; Cost-Benefit Analysis; Herpes Zoster; Herpes Zoster Vaccine; Humans; Italy; Middle Aged; Quality of Life; Aging; Vaccination; Aging; Geriatrics and GerontologyAgedbusiness.industryTetanusVaccinationHerpes zoster; Immunosenescence; Vaccine; Aging; Geriatrics and GerontologyMiddle Agedmedicine.diseaseComorbidityVaccinationItalyQuality of LifeGeriatrics and GerontologybusinessVaccineVaccine; Herpes zoster;Immunosenescence
researchProduct

2017

Summary Background As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016. Methods We estimated prevalence and incidence for 328 diseases and injuries and 2982 sequelae, their non-fatal consequences. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between inc…

Gerontologymedicine.medical_specialtybusiness.industryMortality rateIncidence (epidemiology)1. No povertyPrevalenceGeneral Medicinemedicine.diseaseComorbidity3. Good health03 medical and health sciences0302 clinical medicineEpidemiologyGlobal healthmedicineLife expectancy030212 general & internal medicine10. No inequalitybusiness030217 neurology & neurosurgeryDepression (differential diagnoses)DemographyThe Lancet
researchProduct

Advanced glycation end products measured by skin autofluorescence are associated with melancholic depressive symptoms - Findings from Helsinki Birth …

2021

Background: Millions of people live with depression and its burden of disease. Depression has an increased comorbidity and mortality that has remained unexplained. Studies have reported connections between advanced glycation end products (AGEs) and various disease processes, including mental health. The present study evaluated associations between AGEs, depressive symptoms, and types of depressive symptoms. Methods: From the Helsinki Birth Cohort Study, 815 participants with a mean age of 76 years were recruited for this cross-sectional study. Characteristics regarding self-reported lifestyle and medical history, as well as blood tests were obtained along with responses regarding depressive…

Glycation End Products AdvancedMaleINVENTORYbiomarkkeritDiseaseComorbidityDISEASE3124 Neurology and psychiatryCohort Studies0302 clinical medicinecohort studiesdepressive disorderMedicine030212 general & internal medicineOXIDATIVE STRESSAdvanced glycation end productskohorttitutkimusDepression (differential diagnoses)POPULATIONkomorbiditeettiMETABOLIC SYNDROMESkinRISKeducation.field_of_studytulehdusDepressionadvanced glycation end products3. Good healthPsychiatry and Mental healthClinical PsychologycomorbiditydepressionLIFE-STYLEFemaleARTERIAL STIFFNESSMENTAL-HEALTHikääntyneetCohort studymasennusmedicine.medical_specialtyPopulation03 medical and health sciencesInternal medicineHumansMedical historyeducationAgedInflammationRECEPTORbusiness.industryDepressive disorderBeck Depression Inventorybiomarkersmedicine.diseaseMental healthComorbidityCross-Sectional Studiesinflammationaineenvaihduntatuotteetbusiness030217 neurology & neurosurgeryBiomarkersJournal of psychosomatic research
researchProduct

Wie oft wird die Depersonalisations-Derealisationsstörung (ICD-10: F48.1) in der ambulanten Versorgung diagnostiziert?

2010

Zusammenfassung Fragestellung: Untersucht wird erstmalig, wie haufig die Depersonalisations-Derealisationsstorung (ICD-10: F48.1) in der Allgemeinbevolkerung unter Alltagsbedingungen diagnostiziert wird und mit welchen weiteren Krankheitsgruppen sie assoziiert ist. Methode: Die Untersuchungspopulation umfasst 1.567 Millionen Versicherte einer gesetzlichen Krankenkasse (Gmunder Ersatzkasse). Analysiert wird die Einjahrespravalenz der Diagnose F48.1 sowie deren Assoziation mit anderen ICD-10-Diagnosenschlusseln. Ergebnis: Es fand sich eine Einjahrespravalenz fur die Diagnose F48.1 von 0.007 %. Nach Adjustierung fur Alter, Geschlecht, Depression und Angst waren unter anderem folgende somatisch…

Gynecologymedicine.medical_specialtybusiness.industryHealth care servicemedicineICD-10medicine.diseasebusinessComorbidityDepersonalization-derealization disorderZeitschrift für Psychosomatische Medizin und Psychotherapie
researchProduct

Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP).

2012

Abstract B-type natriuretic peptide (BNP) is a member of a four-natriuretic peptide family that shares a common 17-peptide ring structure. The N-terminal fragment (NT-pro-BNP) is biologically inert, but both are secreted in the plasma in equimolar quantities and both have been evaluated for use in the management of congestive heart failure. BNP and NT-pro-BNP are frequently used in the diagnosis of congestive heart failure and distinguishing between patients with dyspnoea of cardiac or pulmonary origin. Values of NT-pro-BNP are affected by age or the presence of one or several co-morbidities such as chronic renal failure, type 2 diabetes, and acute coronary syndrome. ‘Normal’ values of thes…

Heart FailureAge FactorsReproducibility of ResultsComorbidityReview ArticlePrognosisSeverity of Illness IndexPeptide FragmentsDiagnosis DifferentialDyspneaPredictive Value of TestsRisk FactorsNatriuretic Peptide BrainHumansnatriuretic peptidesprognostic valueshormones hormone substitutes and hormone antagonistsBiomarkersNT-pro-BNPCardiovascular journal of Africa
researchProduct

Temporal trends and predictors of inhospital death in patients hospitalised for heart failure in Germany.

2020

Abstract Aims We investigated trends in incidence, case fatality rate, patient characteristics and adverse inhospital events of patients hospitalised for heart failure in Germany. Methods and results The German nationwide inpatient sample (2005–2016) was used for this analysis. Patients hospitalised due to heart failure were selected for analysis. Temporal trends in the incidence of hospitalisations, case fatality rate and treatments were analysed and predictors of inhospital death were identified. The analysis comprised a total number of 4,539,140 hospitalisations (52.0% women, 81.0% aged ≥70 years) due to heart failure. Although hospitalisations increased from 381 (2005) to 539 per 100,00…

Heart transplantationHeart FailureMalemedicine.medical_specialtyEpidemiologybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPatient characteristicsComorbiditymedicine.diseaseHospitalizationHeart failureGermanyCase fatality rateEmergency medicineMedicineHumansIn patientFemaleHospital MortalityCardiology and Cardiovascular MedicinebusinessAgedEuropean journal of preventive cardiology
researchProduct

Propuestas para un enfoque transdiagnóstico de los trastornos mentales y del comportamiento: Evidencia, utilidad y limitaciones = Proposals for a tra…

2012

The high rates of comorbidity and cross-sectional covariation between disorders are oneof the main limitations of current psychiatric diagnostic approaches, which moreover are based oncategories defined by clinical features rather than assumptions about etiology. These limitations areespecially manifest as regards anxiety and depressive disorders, and also are evident in eating disorders.The accumulating evidence on symptom overlap has led several authors to suggest the existenceof common and shared pathology dimensions across anxiety and depressive disorders,postulating a transdiagnostic approach to these disorders. At the same time, transdiagnostic treatmentsfor emotional disorders have b…

High ratePsychiatry and Mental healthClinical PsychologyEtiologymedicineAnxietymedicine.symptommedicine.diseasePsychologyComorbidityPsicologíaClinical psychologyRevista de Psicopatología y Psicología Clínica
researchProduct

HSP10,HSP70 AND HSP90 IMMUNOHISTOCHEMICAL LEVELS CHANGE IN ULCERATIVE COLITIS AFTER THERAPY

2011

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by damage of large bowel mucosa and frequent extra-intestinal autoimmune comorbidities. The role played in IBD pathogenesis by molecular chaperones known to interact with components of the immune system involved in inflammation is unclear. We previously demonstrated that mucosal Hsp60 decreases in UC patients treated with conventional therapies (mesalazine, probiotics), suggesting that this chaperonin could be a reliable biomarker useful for monitoring response to treatment, and that it might play a role in pathogenesis. In the present work we investigated three other heat shock protein/molecular chaperones:…

HistologyBiophysicsDown-RegulationInflammationcomorbidity.Inflammatory bowel diseaseulcerative colitis heat shock proteins Hsp molecular chaperones inflammation comorbidity.Pathogenesischemistry.chemical_compoundMesalazineulcerative colitis heat shock proteins Hsp molecular chaperones inflammation comorbidityHeat shock proteinChaperonin 10MedicineHspHumansHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsColitisMesalaminelcsh:QH301-705.5ulcerative colitisbusiness.industryBrief Reportmolecular chaperonesAnti-Inflammatory Agents Non-SteroidalCell Biologymedicine.diseaseUlcerative colitisImmunohistochemistrydigestive system diseaseschemistrylcsh:Biology (General)inflammationImmunologyheat shock proteinsBiomarker (medicine)Colitis Ulcerativemedicine.symptombusiness
researchProduct